$SWVLBullishMed

Swvl Announces Q1 2026 Results; Revenue Up 68%; GCC Revenue Up 111%; Dollar-Pegged Revenue Up 111% and Net Dollar Retention of 114%

Swvl Holdings reported Q1 2026 results for the three months ended March 31, 2026: revenue rose 68% year over year to $8.2M, with GCC revenue up 111% to $3.6M and Egypt revenue up 45% to $4.6M. Gross profit increased 63% to $1.6M. The operating loss narrowed 71% to $0.17M (operating margin -2%). Recurring revenue was 88% and dollar-pegged revenue 44%, with net dollar retention of 114%.

8/10
8/10
Med
Bullish
Q1 2026 results press release (published today)
Improving profitability and retention metrics align with a risk-on earnings read-through for growth/recurring-revenue models.

Results show accelerating enterprise demand (GCC) plus improving revenue quality (recurring/dollar-pegged) and operating leverage.

Swvl reported Q1 2026 revenue up 68% to $8.2M, GCC revenue up 111%, and narrowed operating loss 71% toward breakeven.

Likely positive near-term bias as traders price in improving profitability trajectory and stronger hard-currency recurring mix.

Background

Swvl is a technology-enabled mass mobility provider; this release reports Q1 2026 results for the three months ended March 31, 2026.

Why it matters

The key new information is the quantified improvement across growth (revenue +68%, GCC +111%), revenue quality (recurring 88%, dollar-pegged 44%), retention (NDR 114%), and cost discipline (operating expenses 23% of revenue), with operating loss narrowing 71% toward breakeven.

Market relevance

A quantified earnings print with multiple forward-looking operating KPIs (NDR, recurring/dollar-pegged mix) that can re-rate expectations for profitability and FX resilience.

Market effects

Supports the narrative that enterprise mobility platforms can scale with operating leverage and higher retention, potentially improving sentiment toward similar listed mobility/vertical SaaS-like models.

Highlights GCC and Egypt as growth engines, which may influence regional investor appetite for MENA-focused growth platforms.

Dollar-pegged revenue growth suggests reduced FX risk and more hard-currency earnings visibility, relevant for global investors assessing EM/MENA exposure.

Alternative perspectives

Despite strong growth, Swvl still reported a pre-tax loss and gross margin slightly declined, so the quality of profitability improvement may be less durable than the headline suggests.

The article attributes the pre-tax swing partly to non-cash fair-value items; traders may want to separate operating progress from valuation effects and watch cash flow/working-capital trends next.

Key entities

  • Swvl Holdings Corp

    Reported Q1 2026 revenue growth, GCC acceleration, improved retention, and narrowed operating loss.

  • Mostafa Kandil

    CEO quote framing the FY2025 inflection as durable and pointing to UK/US launch plans.

  • Ahmed Misbah

    CFO quote emphasizing operating leverage and revenue mix strengthening.

Related articles

$SWVLMed

Swvl Expands its Service into Saudi Arabia's Banking Sector with Bank Albilad, Bringing Technology-Driven Shuttle Services that Redefine Workforce Mobility

Swvl Holdings (Nasdaq: SWVL) said it signed a contract with Saudi bank Albilad to provide technology-enabled shuttle services across the bank’s network, using Swvl’s platform for route planning, real-time dispatch, and operational optimization. Swvl cited prior GCC contract wins, including Kuwait up to $2.2M, UAE up to $5.5M, and Saudi healthcare up to $1.5M.

$DALMedAI 8/10

Delta reaffirms ’26 profit guidance | Arkansas Democrat Gazette

Delta Air Lines reaffirmed full-year 2026 adjusted earnings guidance of $6.50 to $7.50 per share, citing strong demand for premium, corporate and international travel that offset record quarterly fuel costs. Delta reported Q2 adjusted EPS of $1.56, above $1.51 expected, with revenue up 14% and capacity up 1%. Shares fell 1.8% to $87.39. Adjusted fuel expense was $4.4B, up 77%.

$AZNHighAI 8/10

AstraZeneca Plunges After New Heart Disease Drug Fails Trial

AstraZeneca said its heart disease drug Wainua failed to beat placebo in a clinical trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to AstraZeneca and Ionis Pharmaceuticals. AstraZeneca shares fell up to 10.6% in London and 5.7% on the NYSE. Rival ATTR-CM drug makers Pfizer, BridgeBio, and Alnylam initially moved higher or lower.

$WDFCMedAI 8/10

WD-40 Q3 Earnings Call Highlights

WD-40 Company (NASDAQ:WDFC) reported Q3 gross margin of 56.6% and non-GAAP net income of $31.5 million, with non-GAAP EPS of $2.33. EMEA sales rose 17% to $66.6 million and Asia-Pacific sales rose 24% to $27.3 million. FY2026 constant-currency net sales guidance is $652 million to $667 million. The board authorized a $100 million share repurchase program.

$RXSTMedAI 8/10

RxSight Q2 Sales Sink 20% as Alcon Deal Bolsters 2026 Outlook

RxSight (NASDAQ:RXST) reported Q2 sales of 11 Light Delivery Devices (LDDs) and one LDD rental, lowering sales 20% and leaving an installed base of 1,166 units. Cash, cash equivalents and short-term investments were about $209M. It revised 2026 revenue to $140M-$160M, including $110M-$120M RxSight sales and $30M-$40M Alcon collaboration revenue, and raised gross margin outlook to 73%-75%.

$WDFCHighAI 9/10

Why WD-40 Stock Popped Today

WD-40 (WDFC) shares rose after the company reported fiscal 2026 Q3 net sales up 24% to $195 million and adjusted EPS of $2.33, above the $1.56 estimate. Operating income increased 47% to $40.3 million. WD-40 raised full-year guidance to net sales of $675-$690 million and adjusted EPS of $6.05-$6.35.